UPCC 06717 / AMC 101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
Brief description of study
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Non-Hodgkin lymphoma,Diffuse Large B-cell Lymphoma,HIV+,
-
Age: Between 18 Years - 64 Years
-
Gender: All
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting